EXHIBIT 99.1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of Matinas BioPharma Holdings, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filings.

 

The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

 

This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of July 3, 2017.

       
  GJG Life Sciences, LLC  
       
  By: 

/s/ GJG Capital, LLC

 
    GJG Capital, LLC  
    Managing Member  
    By: /s/ Jennifer Lorenzo, Managing Member  

       
  GJG Capital, LLC  
       
  By: 

/s/ Jennifer Lorenzo

 
    Jennifer Lorenzo  
    Managing Member  

   
  /s/ Jennifer Lorenzo
 

Jennifer Lorenzo